Gland and Hormone Related Diseases

All Conditions

Neoplasms

Thyroid Diseases

Thyroid Neoplasms

Endocrine System Diseases

Endocrine Gland Neoplasms

Head and Neck Neoplasms

All Drugs and Chemicals

Micronutrients

Anti-Infective Agents

Antibodies

Immunoglobulins

Iodine

Cadexomer iodine

Thyroid cancer group: patients with differentiated or dedifferentiated thyroid cancer Healty: control group

Zekiye Hasbek, M.D.

In clinical practise patients with negative radioiodine scan with positive tyhroglobulin is considered as radioiodine resistant or in another words in the process of dedifferentiation. The aim of the present study was to search a simple blood test that could lead to early identification of patients with dedifferentiation. In this respect, we investigate whether the serum level of anti-p53 antibody has the diagnostic value in the follow-up of patients with high levels of thyroglobulin (tg) and negative I-131 scan.

In the present study enrolled were 171 patients with mean age of 47.7±13.5 yrs (range; 16-80yrs) and 28 healthy subjects with an age range of 18-52 yrs (mean: 36.0±9.8 yrs). 134 (78.4%) patients were female and 37 (21.6%) patients were male.

P53 in Differentiated Thyroid Cancer

P53 Antibody; Is it an Indicator of Dedifferentiated Thyroid Cancer?

Cumhuriyet University

Cumhuriyet University, School of Medicine, Department of Nuclear Medicine

Eye Diseases

Carcinoma

Lacrimal Apparatus Diseases

50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma undergoing radioactive iodine therapy

50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma not undergone radioactive iodine therapy

Radioiodine therapy

Suzana Matayoshi, Professor

The radioactive radioiodine therapy (Na131I) for the treatment of differentiated thyroid carcinoma is a procedure used for ablation of remaining thyroid tissue after thyroidectomy and metastases. Although serious complications are uncommon after treatment, there are well-documented adverse reactions secondary to the involvement of the salivary glands, such as dry mouth, pain in the parotid glands and dysphagia, even after administration of low doses of radioiodine. However, ocular complications of such treatment are scarcely reported in literature.

Among them the investigators can mention recurrent and chronic conjunctivitis, keratoconjunctivitis sicca and dry eye, affecting 23% of patients undergoing radioactive iodine therapy. Dysfunction of the lacrimal gland is described in recent studies, especially after high cumulative dose of the drug. Likewise, epiphora and nasolacrimal duct obstruction have been reported as complications associated with the use of radioiodine, although studies are not available to assess its true incidence through the systematic evaluation of patients.

It can be seen in routine practice that these patients would normally be referred for ophthalmological examination only if a complaint, what happens in the process of OVL already installed after the use of high doses of radioiodine. With the early evaluation of these patients, the investigators focused on detecting the process of ongoing obstruction in order to study interventions that prevent its final installation.

Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma

Fabricio Lopes da Fonseca

Principal Investigator

Rare Diseases

Thyroid Cancer, Papillary

Adenocarcinoma, Follicular

Papillary Thyroid Carcinoma

Thyroid Cancer, Follicular

Hurthle Cell Thyroid Cancer

Patients will be randomised to receive Radioactive iodine (RAI) ablation I131 1.1 GBq

Patients will be randomised to receive No Radioactive iodine (No-RAI) ablation

I131 1.1 GBq

Ujjal Mallick, MBBS, Master of Surgery, FRCR

IoN is a phase II/ III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients.

Phase II: to determine if recruitment into a phase III trial is feasible, with a target of 10 patients per month during a minimum of 6 months (evaluated within months 7-18 of the trial).

Phase III: to determine whether the 5-year disease-free survival rate among patients who do not have routine Radioactive iodine (RAI) ablation is non-inferior to those who do.

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

To determine if recruitment into a phase III trial is feasible

DFS measured from randomisation until date of recurrence or death from thyroid cancer

Both groups will be compared to ascertain if radio-iodine results in a statistically significant reduction in risk in developing loco-regional recurrence in the low risk subgroup of patients.

Both groups will be compared to ascertain if radio-iodine results in a statistically significant difference in the stage of cancer at the time of recurrence, and the ability to treat this successfully.

Adverse events will be collected for patients in both groups during treatment and the groups compared during analysis.

The number of further neck surgeries will be collected for patients in both groups during follow up and the groups compared during analysis.

Further RAI ablation and the reasons for this

Costs of treatment for both groups will be collected for duration of trial to see if there is a difference between the two.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
P53 in Differentiated Thyroid Cancer	NCT01954134	Thyroid Neoplas...		16 Years - 80 Years	Cumhuriyet University
Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma	NCT01579344	Lacrimal Appara...	Radioiodine the...	18 Years -	University of Sao Paulo
Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma	NCT01579344	Lacrimal Appara...	Radioiodine the...	18 Years -	University of Sao Paulo
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients	NCT01398085	Thyroid Cancer	I131 1.1 GBq	16 Years -	University College, London
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients	NCT01398085	Thyroid Cancer	I131 1.1 GBq	16 Years -	University College, London

Spots Global Cancer Trial Database for iodine radioisotopes